Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation
about
Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv miceThe prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particlesThe sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acidAlkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.Characterization of a novel type of HIV-1 particle assembly inhibitor using a quantitative luciferase-Vpr packaging-based assayStructural and functional insights into the HIV-1 maturation inhibitor binding pocketStructure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396Identification of potent maturation inhibitors against HIV-1 clade CThe inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in GagElectron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells.Anti-leishmanial activity of betulin derivatives.The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical IsolatesEffect of dimerizing domains and basic residues on in vitro and in vivo assembly of Mason-Pfizer monkey virus and human immunodeficiency virus.Anti-AIDS agents 81. Design, synthesis, and structure-activity relationship study of betulinic acid and moronic acid derivatives as potent HIV maturation inhibitorsIonic derivatives of betulinic acid as novel HIV-1 protease inhibitors.Inhibitory effect of aqueous Dandelion extract on HIV-1 replication and reverse transcriptase activityCurcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription.A small-molecule antagonist of virion assembly.HIV entry inhibitors and their potential in HIV therapyRecent advances in proteasome inhibitor discovery.New anti-HIV agents and targets.Anti-staphylococcal, anti-HIV and cytotoxicity studies of four South African medicinal plants and isolation of bioactive compounds from Cassine transvaalensis (Burtt. Davy) codd.In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).New betulinic acid derivatives as potent proteasome inhibitorsBifunctional anti-human immunodeficiency virus type 1 small molecules with two novel mechanisms of action.HIV-1 Gag as an Antiviral Target: Development of Assembly and Maturation Inhibitors.Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice.Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage.Anti-AIDS agents 88. Anti-HIV conjugates of betulin and betulinic acid with AZT prepared via click chemistryThe discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV.Anti-AIDS agents 90. novel C-28 modified bevirimat analogues as potent HIV maturation inhibitors.Dimerization of the SP1 Region of HIV-1 Gag Induces a Helical Conformation and Association into Helical Bundles: Implications for Particle Assembly.Two New 3,4;9,10-seco-Cycloartane Type Triterpenoids from Illicium difengpi and Their Anti-Inflammatory ActivitiesSmall-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation.Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly.Recent progress in antiretrovirals--lessons from resistancePA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C
P2860
Q21092230-E6EE0FC6-568F-49F2-868A-93D8988141D1Q21245046-4BFF5DE1-FCC3-4ECB-A24F-476A8CCF3439Q24793247-C34C1BA0-12D5-4E96-B2B1-A2BEC174CD6DQ27324263-D746EF08-05F2-4801-A3D1-0F57661C0ADBQ28477791-9DE2D6C2-3153-43B0-A272-E68120498E56Q28485054-C552DE40-2606-46F0-9ED3-5DFC92A95DBFQ28828191-B9E43BCF-6FFE-49D7-BB6D-5AF4E3369809Q28829072-4CA610B1-9D9F-433A-8437-C231B2BDEAEFQ30440445-06062F73-981D-40CE-9109-A39295A21DD7Q30478394-505FD9F9-97EE-4868-BFD5-AB9FD9E973C0Q30479297-BA7DE779-4BDE-450D-BF72-1F0D38CB65DFQ33530052-952843B5-9F08-4430-93CB-8466D57C8480Q33557807-90CD8654-ABE3-45A3-8E3E-6D21F13756ECQ33614514-8362AFBC-A819-434E-815C-7A936537E37DQ33814879-4DB08979-4205-4D4D-ABCC-23C0DC370931Q34045239-5FEAFB9F-C347-4B83-91BC-9F0406F54371Q34073041-F9BF1A03-C6C6-446B-8616-72DE418EF03CQ34350588-1F209597-B665-487F-868B-7A1731F0C09BQ34489215-49E2545D-EF00-4B29-8CBD-2DB19594DEE0Q34595921-7831C709-A0F9-4D8C-9AB6-443B492DCE9AQ34645067-E2663109-FA61-4E9B-B27F-C23FFBC75934Q34944447-0C468F8B-D820-407B-B5B8-565F92AF11E5Q35059847-BA658F38-F7EB-4C2F-80DE-BCBCDAEBCF4EQ35139703-F4EC15D7-CB67-4FCD-8D98-AF8B751AB74AQ35209514-D409DE49-B6EB-49F7-939C-EC1D052BC8E0Q35548195-F9CAB0F9-A260-4EE9-A4E1-931DA3EA8C95Q35761626-334D992F-8031-49EB-BA04-FD026BD45075Q35832693-E2111078-409E-48E2-923E-9AFD4DF3EC09Q35992805-A98CD47D-E454-498C-9DA0-1C5B81AFE70EQ36034205-27F94132-560A-438A-86D6-32199CC1B8EFQ36187060-52352A1D-E946-4CE9-80F9-568A3CC4E8C8Q36340098-68EC9651-C8E7-464A-B391-1064AA3CADCFQ36523929-1B3CAFBF-1818-423E-BC39-E3F3C949F118Q36898695-1F7D7D81-8074-42C6-8F3C-C12A12791E22Q36944553-D8CEA443-DCB0-4715-A422-343B6F94EEA7Q36950909-9F933878-069D-4D67-A733-CAAAE1850F89Q36967857-9C672C94-588F-45E6-9D8F-69F30295E297Q37089562-76C59D2A-2442-4DDF-9F66-644C7F5F28B5Q37192174-4A06924B-E98C-4CFD-85FC-573C81BF4863Q37676344-C1BB1981-EC75-485B-A335-8682F771D2C0
P2860
Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Anti-human immunodeficiency vi ...... ound blocking viral maturation
@ast
Anti-human immunodeficiency vi ...... ound blocking viral maturation
@en
Anti-human immunodeficiency vi ...... ound blocking viral maturation
@nl
type
label
Anti-human immunodeficiency vi ...... ound blocking viral maturation
@ast
Anti-human immunodeficiency vi ...... ound blocking viral maturation
@en
Anti-human immunodeficiency vi ...... ound blocking viral maturation
@nl
prefLabel
Anti-human immunodeficiency vi ...... ound blocking viral maturation
@ast
Anti-human immunodeficiency vi ...... ound blocking viral maturation
@en
Anti-human immunodeficiency vi ...... ound blocking viral maturation
@nl
P2093
P2860
P3181
P1476
Anti-human immunodeficiency vi ...... ound blocking viral maturation
@en
P2093
H Nakashima
M Yoshimori
T Kanamoto
Y Kashiwada
P2860
P304
P3181
P356
10.1128/AAC.45.4.1225-1230.2001
P407
P577
2001-04-01T00:00:00Z